Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
LY2880070
DRUG
2 trials
Sponsors
Esperas Pharma Inc.
, Memorial Sloan Kettering Cancer Center
Conditions
Breast Cancer
Colon Cancer
Colorectal Cancer
Endometrial Cancer
Ewing Sarcoma
Ewing-Like Sarcoma
Neoplasms
Ovarian Cancer
+6 more
Phase 1
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Completed
NCT02632448
Esperas Pharma Inc.
Breast Cancer, Colon Cancer, Colorectal Cancer +9
Start: 2016-05-16
End: 2025-04-14
Target: 229
Updated: 2025-05-02
Phase 2
A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor
Completed
NCT05275426
Memorial Sloan Kettering Cancer Center
Ewing-Like Sarcoma, Ewing Sarcoma
Start: 2022-03-02
End: 2025-08-11
Updated: 2025-08-15
Related Papers
Abstract B005: A phase 1 expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose gemcitabine in metastatic pancreatic adenocarcinoma
Cancer Research
2024-01-16
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Clinical Cancer Research
2023-10-11
10 citations
A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer.
Journal of Clinical Oncology
2020-05-20
13 citations
A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer.
Journal of Clinical Oncology
2020-05-20
7 citations